IL278978B2 - Preparations and methods for treating psoriasis - Google Patents

Preparations and methods for treating psoriasis

Info

Publication number
IL278978B2
IL278978B2 IL278978A IL27897820A IL278978B2 IL 278978 B2 IL278978 B2 IL 278978B2 IL 278978 A IL278978 A IL 278978A IL 27897820 A IL27897820 A IL 27897820A IL 278978 B2 IL278978 B2 IL 278978B2
Authority
IL
Israel
Prior art keywords
antibody
seq
psoriasis
subject
fragment
Prior art date
Application number
IL278978A
Other languages
English (en)
Hebrew (he)
Other versions
IL278978A (en
IL278978B1 (en
Original Assignee
Abcentra Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcentra Llc filed Critical Abcentra Llc
Publication of IL278978A publication Critical patent/IL278978A/en
Publication of IL278978B1 publication Critical patent/IL278978B1/en
Publication of IL278978B2 publication Critical patent/IL278978B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
IL278978A 2018-05-29 2019-05-29 Preparations and methods for treating psoriasis IL278978B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862677590P 2018-05-29 2018-05-29
PCT/US2019/034423 WO2019232070A1 (en) 2018-05-29 2019-05-29 Compositions and methods for treatment of psoriasis

Publications (3)

Publication Number Publication Date
IL278978A IL278978A (en) 2021-01-31
IL278978B1 IL278978B1 (en) 2025-09-01
IL278978B2 true IL278978B2 (en) 2026-01-01

Family

ID=68697289

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278978A IL278978B2 (en) 2018-05-29 2019-05-29 Preparations and methods for treating psoriasis

Country Status (9)

Country Link
US (2) US12016921B2 (https=)
EP (1) EP3801590A4 (https=)
JP (1) JP7357646B2 (https=)
KR (1) KR102940600B1 (https=)
CN (1) CN112689512B (https=)
AU (1) AU2019279883B2 (https=)
CA (1) CA3101767A1 (https=)
IL (1) IL278978B2 (https=)
WO (1) WO2019232070A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US11690912B2 (en) * 2018-05-29 2023-07-04 Abcentra, Llc Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
EP4058042A4 (en) * 2019-11-12 2023-12-27 Abcentra, LLC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2025151468A1 (en) * 2024-01-08 2025-07-17 Abcentra, Llc Methods of identifying a subject for treatment with antibodies against oxidized low density lipoprotein using pericoronary fat attenuation index

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2008104194A1 (en) 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
US8557767B2 (en) * 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
UA100255C2 (uk) * 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Фармацевтична композиція
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
KR20120111724A (ko) 2009-08-28 2012-10-10 제넨테크, 인크. 항-산화된 ldl 항체를 이용한 치료 방법
MX2013003920A (es) * 2010-10-06 2013-06-03 Abbvie Inc Metodos para el tratamiento de la psoriasis.
WO2016024254A1 (en) 2014-08-15 2016-02-18 Fundació Hospital Universitari Vall D’Hebron-Institut De Recerca Therapy selection for psoriasis and psoriatic arthritis
US11690912B2 (en) 2018-05-29 2023-07-04 Abcentra, Llc Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody

Also Published As

Publication number Publication date
EP3801590A1 (en) 2021-04-14
EP3801590A4 (en) 2022-03-16
WO2019232070A1 (en) 2019-12-05
US20250161440A1 (en) 2025-05-22
CN112689512A (zh) 2021-04-20
JP7357646B2 (ja) 2023-10-06
IL278978A (en) 2021-01-31
KR20210044742A (ko) 2021-04-23
US12016921B2 (en) 2024-06-25
US20210205448A1 (en) 2021-07-08
AU2019279883A1 (en) 2021-01-21
KR102940600B1 (ko) 2026-03-18
CN112689512B (zh) 2025-09-05
CA3101767A1 (en) 2019-12-05
AU2019279883B2 (en) 2025-05-22
JP2021530438A (ja) 2021-11-11
IL278978B1 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
US20250161440A1 (en) Compositions and methods for treatment of psoriasis
US11214621B2 (en) Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
CN105517570B (zh) 通过施用il-4r拮抗剂治疗鼻息肉症的方法
US12458694B2 (en) Methods for treatment of accelerated atherosclerosis and rheumatoid arthritis with an anti-Apo B100 antibody
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
KR20240155388A (ko) 두부 판상 건선을 가진 대상체의 치료 방법
US20220177568A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
HK40052952A (en) Compositions and methods for treatment of psoriasis
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
TW202511290A (zh) 一種重組抗IL-23p19抗體治療中重度銀屑病的方法
WO2024155810A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy
TW202521154A (zh) 既往接受生物製劑治療斑塊狀銀屑病的受試者轉用抗IL23p19抗體治療斑塊狀銀屑病的方法
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
KR20260057215A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료